letrozole,palbociclib
pfizer,novartis
['bcsm', 'paloma-2', 'palbociclib']
paloma-2 overall survival analysis of first-line palbociclib + letrozole vs placebo + letrozole. os not statistically significant; limited by large amount of missing data. 10% of patients continue on palbo + letrozole after 7.5 years.
#asco22 #bcsm richard finn of 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.